Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 kicks off in Las Vegas, Nevada, on Wednesday, April 22, 2026. As the global burden of 

, and other related conditions continues to rise, this year's conference is set to explore the latest evidence-based strategies, clinical innovations, and interdisciplinary approaches that position nutrition as both a therapeutic tool and a foundation for lifelong health.

The meeting is structured to provide relevant, practical, and immediate application of clinical education for endocrinologists, fellows, primary care physicians, physicians assistants, nurse practitioners, nurses, diabetes care and education specialists, clinical pharmacists, registered dietitians, and others in the endocrine care team. This year’s AACE meeting boasts more than 2200 attendees, 110 speakers, and 80 sessions across the 3-day conference.

 editorial team will be on site at the conference, providing written coverage of practice-shifting data as well as interviews with key experts. You can keep up with our comprehensive conference coverage 

. Check out what can be expected from this year’s meeting below:

 who will discuss advances in prediabetes and diabetes prevention as well as multidisciplinary approaches to MASLD and MASH

who will discuss clinical outcomes associated with continuation versus discontinuation of insulin pump therapy in hospitalized adults with diabetes as well as GLP-1 use in type 1 diabetes and obesity

 who will discuss whether clinicians should continue to use BMI when talking about obesity

 who will discuss 2-year results from the CAHtalyst Adult study of crinecerfont in adults with classic congenital adrenal hyperplasia

Tirzepatide vs Semaglutide for Glycemic Control and Weight Loss: Updated Network Meta-Analysis of Phase 3 Trials Incorporating 2025 SURMOUNT-5 Data

 Mohamed Ahmed, MD, and Sameer Bhimani, MD

Characterization of Proptosis Response Among Responders Treated with Veligrotug in the THRIVE Phase 3 Trial for Active Thyroid Eye Disease (TED)

 Jody Abrams, MD, Steven Leibowitz, MD, Raghu Mudumbai, MD, et al

Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Fasting Blood Glucose

Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Post Prandial Blood Glucose

Correlation of Weight loss and 36-Item Short Form Survey Total score in weight management with Semaglutide injection: Post-hoc Analysis of Phase 3 Study

 Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

Relacorilant Treatment Improves Glycemic Control Among Individuals With Endogenous Hypercortisolism and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

 Julie Silverstein, MD, Georgiana Dobri, MD, Atanaska Elenkova, MD, et al

Crinecerfont Improves Cardiometabolic Outcomes Associated With Chronic Supraphysiologic Glucocorticoid Exposure: 1-Year Results from CAHtalyst™ Adult

 Oksana Hamidi, DO, MSCS, Irina Bancos, MD, Nicole Reisch, MD, et al.

Articles

AACE Annual Meeting 2026 convenes April 22–24 in Las Vegas with a nutrition-forward agenda amid accelerating burdens of obesity, diabetes, dyslipidemia, and related cardiometabolic disease. The program targets rapid clinical translation for the full endocrine care team and features 2,200+ attendees, 110 speakers, and 80 sessions. Planned expert discussions include diabetes prevention, inpatient insulin pump management, GLP-1 use in type 1 diabetes/obesity, MASLD/MASH multidisciplinary care, BMI’s role in obesity communication, and 2-year crinecerfont data in classic CAH.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

AACE Annual Meeting 2026 Preview: 7 Trials to Know

Silvia Mariel Ferrucci, MD, is an adjunct professor of dermatology at the University of Milan and the head of the the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

New real-world 3-year data from the multinational GLOBOSTAD study suggest that dupilumab therapy (Dupixent) demonstrates sustained efficacy and safety in patients with 

These findings resulted from a poster presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado. These real-world insights in the overall population treated with dupilumab were discussed in a new interview with Silvia Mariel Ferrucci, MD, an adjunct professor of dermatology at the University of Milan and head of the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

 highlights Ferrucci’s responses to inquiries about her team’s findings and their significance in the 2026 treatment landscape:

Can you give an overview of the GLOBOSTAD study and what makes this dataset particularly valuable for understanding long-term outcomes with dupilumab?

GLOBOSTAD is a global study to evaluate the impact of dupilumab (or Dupixent) on disease outcomes in clinical practice. Observational studies like this provide further evidence about the safety and efficacy of approved treatments, like Dupixent, in real-world settings and also allow us to evaluate treatment effect in a large, diverse cohort of patients over time. Long-term evaluation of atopic dermatitis is particularly important as it’s a chronic disease where many factors, including environmental changes, can instigate flare-ups throughout and over the years.

What was the overall design of this study, and how does its real-world, observational nature shape how we should interpret the findings?

The study enrolled patients 12 years of age and older with moderate-to-severe atopic dermatitis who were receiving Dupixent based on country-specific prescribing information. Outcomes were assessed at baseline, 3 months, 6 months and then every 6 months up to 3 years for this interim analysis. The study is ongoing and will evaluate patients for 5 years.

The study adds real-world evidence that further supports the established ability of Dupixent to improve signs and symptoms of atopic dermatitis, but because GLOBOSTAD is not a randomized, placebo-controlled trial, definitive conclusions about safety and efficacy cannot be made based on these results.

At the 3-year mark, what stood out most to you in terms of sustained effectiveness for patients with atopic dermatitis?

In a diverse, real-world population, Dupixent showed sustained effectiveness on measures of disease severity as well as patient-reported symptom severity, itch and health-related quality of life over 3 years compared to baseline. Importantly, the mean values for disease severity, patient-reported symptoms and itch were in the mild/no disease range and patients reported no-to-small effect on health-related quality of life at 3 years of Dupixent treatment.

How did the safety profile of dupilumab evolve over time in this real-world population?

 The safety profile was consistent with the known safety profile of Dupixent. Adverse events occurring in at least 5% of patients included allergic conjunctivitis, COVID-19 and conjunctivitis, with most having resolved or were resolving at the end of the observation period.

 Based on these long-term data, what do you think are the key clinical implications for dermatologists managing patients with moderate-to-severe atopic dermatitis?

Dupixent is already approved for eligible patients with atopic dermatitis in several countries around the world, so long-term, real-world analyses like these provide further evidence about the value Dupixent can bring to reducing disease burden for atopic dermatitis patients in clinical practice. Additionally, GLOBOSTAD will collect data about the impact of Dupixent on outcomes related to coexisting type 2 diseases, like asthma, which could also help inform clinical decision making for patients with comorbid conditions.

The quotes used in this Q&A interview summary were edited for clarity.

Ferrucci has served as a principal investigator in clinical trials for AbbVie, Almirall, Galderma, Leo Pharma, Sanofi, Amgen, and Novartis, Bayer, and received honoraria for lectures for Novartis and Menarini.

Ferrucci S, et al. Dupilumab Shows Sustained Effectiveness and Safety in Patients with Atopic Dermatitis: Real-World Insights from the Overall Population 3 Years into the GLOBOSTAD Multinational Prospective Observational Study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Smith T. Dupilumab Treatment of Atopic Dermatitis Safe for Up to 5 Years in Children, Adults. HCPLive. December 12, 2024. Accessed April 17, 2026. 

https://www.hcplive.com/view/dupilumab-treatment-atopic-dermatitis-safe-up-to-5-years-children-adults

Three-year interim real-world data from the multinational prospective observational GLOBOSTAD cohort support sustained dupilumab effectiveness and a safety profile consistent with established experience in patients ≥12 years with moderate-to-severe atopic dermatitis. Serial assessments from baseline through 36 months showed durable improvements in clinician-assessed severity, patient-reported symptom burden, pruritus, and health-related quality of life, with mean outcomes in the mild/no-disease range at year 3. Common adverse events (≥5%) included conjunctivitis/allergic conjunctivitis and COVID-19, largely resolving by observation end.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average

A population-wide screening program deployed by mobile health units in Detroit, Michigan, found 11-13% had 

 ≥ stage 3,  double the US population’s 6% reported national average.

Additionally, results from the cross-sectional study of the public health outreach program, which used the CKD-EPI 2021 eGFR creatinine formula, found increased incidence among at-risk subgroups, including older individuals, adults who identify as black, and patients with diabetes.

The Gap and Goal Behind CKD Screening in Disadvantaged Communities

“A lot of what we’re striving to do is just get people to want to know their numbers, want to know the information that’s going to lead them to think perhaps differently about prevention, or get awoken to do something more than nothing, which is going to be the only way to take a stage 3 chronic kidney disease patient and keep them off dialysis,” study investigator, Phillip Levy, an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine, shared in an interview with 

This community health program took place in Detroit, Michigan, where 31 to 34% of residents live below the federal poverty line, classifying these neighborhoods as disadvantaged. As such, a majority of individuals reside in environments with social determinants of health that put them at an increased risk for developing CKD. The major social barriers to screening for patients in these communities often remain awareness and access.

HCPLive’s most recent Crisis Point covers the 

cause and effect of neighborhood disadvantage on kidney disease

To address this, the population health program deployed mobile health units across metropolitan Detroit to improve earlier detection of cardiovascular-kidney-metabolic risk factors, decrease area-wide morbidity and mortality, and reduce health disparities.

How Did The Mobile Health Units Operate? What Did We Learn?

5 to 7 Mobile health units were deployed with nonphysician staff, 5 to 6 days per week, to partner locations. After they took a brief medical history, patients ≥ 18 years of age were offered screenings for high blood pressure (BP), diabetes (ie, hemoglobin A[HbA] measurement), and CKD using eGFR.

The cohort included 5128 unique patients with 5973 encounters. Investigators reported that 2293 patients (44.7%) had eGFRs of 60 to 89 mL/min/1.73 m2, whereas 579 (11.3%) had ≥ CKD stage 3(eGFR <60 mL/min/1.73 m2). As reported, patients with older age, Black race, and diabetes, defined as HbA1c ≥6.5%, were associated with higher risks for ≥ CKD stage 3

I think it’s critically important to recognize that when an older individual, an older Black individual, is found to have CKD, it didn’t happen yesterday. It’s been ongoing for a little while,” Levy said. “I’s really important for clinicians to not only impress upon their patients, but educate their patients to be ambassadors for their families and their communities—to say, you’re here, you’re doing the right thing by coming to the doctor’s office today, but what about your aunt, your uncle, your cousin, your mom, your dad?”

A limitation to these findings was an inability to measure urine albumin to creatinine ratio, which investigators suspect, if added, would result in increased rates of CKD stages.

Editor’s Note: Levy report relevant disclosures with Cielo Foundation.

Brook RD, Korzeniewski SJ, Foster B, et al. Screening for Chronic Kidney Disease by Mobile Health Unit Outreach. JAMA Network Open. 2026;9(3):e262312. doi:

https://doi.org/10.1001/jamanetworkopen.2026.2312

Detroit Partnership on Economic Mobility. University of Michigan. Accessed April 16, 2026. 

https://poverty.umich.edu/projects/detroit-partnership-on-economic-mobility/

Videos

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Understanding Patient Preferences in Psoriasis, With Andrew Blauvelt, MD, MBA

As a wave of new oral therapies approaches regulatory review for moderate-to-severe plaque 

 (PsO), a better understanding is needed of what factors may affect patient preference toward different modalities of treatment.

caught up with Andrew Blauvelt, MD, MBA, dermatologist, Blauvelt Consulting, at the 

 held in Denver, Colorado, from March 27-31, to learn more about how the field is coming to better understand and support patient preferences.

In this conversation, Blauvelt pushed back on what he described as a reflexive tendency to assume that the availability of once-daily oral options will automatically translate into patient demand. The reality, he noted, is considerably more nuanced. Across several published preference studies he reviewed, the direction of patient preference varied substantially depending on disease, severity, injection characteristics, and country of origin.

In 1 study comparing patients with atopic dermatitis and psoriasis on the question of route-of-administration preference, the 2 groups diverged: atopic dermatitis patients favored oral therapy, while psoriasis patients expressed a preference for injectable treatment.

 A second psoriasis-specific study found that disease severity modulated preference within the same patient population — those with more moderate disease leaned toward pills, while patients with more severe disease preferred injections.

The implication, Blauvelt noted, is that 2 studies conducted in the same disease reached different directional conclusions depending on how the question was asked and which patients were enrolled.

Geographic context introduced additional variation. A study conducted in Japan found a clear preference for oral therapy, while a comparable study conducted in Germany yielded the opposite result, with German patients favoring injections.

 And a further study found that what mattered most was not simply whether a treatment was injectable, but what kind of injection it was: patients preferred shots when they were infrequent — monthly or less — and not painful, but shifted toward pills when injections were more frequent or associated with discomfort.

Blauvelt framed these findings as relevant context for interpreting the clinical landscape now emerging around envudeucitinib, zasocitinib, and icotrokinra, each of which offers once-daily or twice-daily oral dosing and carries efficacy data approaching or overlapping with injectable biologics in some measures. The case for oral therapy is real, he argued, but it is not universal — and the patients most likely to benefit from the shift to pills may be those with moderate disease, those averse to injections for logistical or geographic reasons, and those in clinical settings where biologic prescribing remains limited. For patients with more severe disease who are already on well-tolerated, infrequent injectable biologics, the calculus may be less straightforward than the narrative around the oral pipeline sometimes suggests.

Blauvelt’s disclosures include Abbvie, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Eli Lilly, Incyte, Janssen, LEO Pharma, Lipidio Pharma, Novartis, Oruka Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, Takeda, and UCB.

Royeck S, et al. Treatment preferences among systemic therapy-naïve patients with atopic dermatitis or psoriasis in Germany: a multicentre study. 

Komine M, et al. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan. 

. 2023;50:766-777. doi:10.1111/1346-8138.16746

Bolt T, Kobayashi H, Mahlich J. Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan. 

. 2019;3(2):255-264. doi:10.1007/s41669-018-0104-1

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.



Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

 in Denver, April W. Armstrong, MD, MPH, of UCLA’s David Geffen School of Medicine, gave the 

 team a comprehensive look at the evolving role of interleukin (IL)-23 inhibition in the management of 

The interview followed her session, ‘IL-23 Innovation: New Data Addressing Plaque Psoriasis.’

 Given the emergence of the IL-23 pathway as a central therapeutic target in recent years, Armstrong touched on the mechanistic rationale behind the pathway’s growing prominence and its role as a key regulator in inflammatory pathways driving not only psoriasis but also related comorbidities such as inflammatory bowel disease.

The following Q&A summary highlights Armstrong’s responses to questions about her session:

The IL-23 pathway has become a central target in psoriasis over the past few years. How would you characterize what makes IL-23 inhibition mechanistically different, and why has it emerged as a therapeutic target?

There are a few things to consider about IL-23 inhibition. We know that IL-23 inhibition is really central in terms of being this master regulator for diseases such as plaque psoriasis. We actually also know it's really important for conditions such as Crohn's disease or ulcerative colitis, oftentimes comorbidities that are important to our dermatology patients who may have inflammatory skin diseases and have an increased risk of those other conditions. Now, when we're thinking about IL-23, why it's important is that it's very key in terms of making sure that in the process of naive T-cell differentiation, these T cells are differentiated into certain types of cells, such as Th17 cells and so forth.

Because of that, it has a tremendous influence in terms of the pathological states, with regard to potentially directing some of the inappropriately elevated levels of differentiation into Th17 cells that can be pathologic in states such as psoriasis. Now, when we have therapies that target the IL-23 pathway, for example, it can be very specifically targeting that of of diseases that are affected by this, namely psoriasis in this case. Also, what we see is that for therapies that are particularly targeting IL-23, oftentimes, there are very high rates of complete and near-complete skin response with some of the biologics that we've had for a long period of time. One of the distinct advantages of IL-23 modulation or inhibition in psoriasis is that it can get that durable response with extended dosing intervals.

Typically, we're thinking about dosing intervals of every 2 months or every 3 months with our injectable biologics. Now, we do have another class, which is IL-17 inhibitors in psoriasis, that are also extremely highly effective. With the newer IL-17 inhibitors, the dosing intervals are getting closer to those of the IL-23 inhibitors. Getting back to IL-23 inhibition, what we see is that a quite distinctive advantage is the favorable long-term safety profile. What we are seeing is that with patients who have been on IL-23 inhibitors for a while, for example, we have now over 6 or 7 years of long-term extension data. What we see is that it continues to be very safe in our patients who've been taking it for a long period of time, and we don't see signals with regard to serious infections or cancer in those patients who have taken it for a very long time.

We know your session also touches on unmet needs across patient populations. Which patient profiles or clinical scenarios still represent the biggest gaps in the management of psoriasis?

We have come a long way in terms of managing our patients who have psoriasis and psoriatic arthritis, and caring for them has really been a pleasure as a dermatologist, along with our rheumatology colleagues, for the past two decades now. That being said, we also still have a number of areas where we have unmet needs. Number one is thinking about patients who may have limited body surface area involvement, but high-impact site involvement, for example, the treatment of patients with palmoplanter diseases. That's still one area that we are trying to figure out how to better manage that particular disease phenotype. We know that patients with palmoplantar psoriasis have one of the most difficult-to-treat phenotypes, and that is something that we're consistently trying to work on. This includes not only the hyperkeratotic type of palmoplantar psoriasis, but also palmoplantar pustulosis.

Another area is thinking about managing comorbidities in our patients with psoriasis. Namely, looking at obesity a little bit closer. We know that many patients with psoriasis, epidemiologically, there are higher rates of obesity in patients with psoriasis, and newer and newer data show that managing their obesity and getting patients to decrease their weight when they are in the obese category can not only improve their cardiovascular health. That intervention may actually have an independent effect, a positive effect, in terms of reducing their psoriasis or psoriatic arthritis disease activity. This is really interesting data. It's newer data, and something that we as a field are continuing to try to understand.

Then finally, we may have patients who have severe psoriasis or psoriatic arthritis and who also have various complex comorbidities, and we’re thinking about how to care for those patients and ensure that the therapies that we have for them can potentially address these other comorbidities. But also, even if we have a therapy that's specifically for psoriasis, psoriatic arthritis, in the context of the other complex comorbidities, how can we make sure that these patients are safely managed by our pharmacological or other interventions?

 Speaking of interventions, there's a growing number of IL-23 inhibitors now available. How are you thinking about selection and differentiation within your own practice?

We have a number of different IL-23 inhibitors that are available. We have the biologics…and we have a newly-approved IL-23 receptor inhibitor. That's an oral peptide, and that's icotrokinra. So, now we have oral therapies for targeting the IL-23 pathway in patients with plaque psoriasis, as well as biologics. Having all these different options, I think, is really great for our patients, because even within the IL-23 class, we have known from the real-world studies that sometimes failing one IL-23 therapy doesn't necessarily mean that they will fail another IL-23 therapy.

A few things when we're considering these different medications: For example, for patients who have moderate to severe plaque psoriasis, when our dermatologists and dermatology and NPs and PAs are thinking oral therapies could benefit that patient population in terms of targeting the il 23 pathway, we can now, we now have FDA-approved therapy for that, and can consider icotrkinra. When we are looking at icotrokinra, the efficacy rates are at the level of biologics. So that's very exciting and really great news for our patients who especially those who have been wanting an oral therapy for a long time.

When we're looking at our patients who may benefit more potentially in terms of biologic therapies, we have tildrakizumab, which I think is really wonderful for patients who have, for example, Medicare coverage. This is because this tildrakizumab is the only medication within the IL-23 class that's covered under Medicare Part B benefits. So for our patients who are our Medicare age, who may not have good supplemental coverage, for example, that's definitely a good choice. Then we also have, for example, guselkumab and risankizumab, which I think as a field we have known for a very long time to have high efficacy in treating our patients with plaque psoriasis. Also, [they have] very good safety data as well. I think those continue to be excellent choices for patients.

The quotes used in this summary were edited for clarity.

Armstrong has served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

Armstrong A, Strober B, Hawkes J, et al. INC01 IL-23 Innovation: New Data Addressing Plaque Psoriasis. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Campbell P. Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis. March 18, 2026. Accessed April 16, 2026. 

https://www.hcplive.com/view/icotrokinra-receives-fda-approval-for-psoriasis

IL-23 has solidified its role as a master upstream regulator in plaque psoriasis pathobiology by shaping naïve T-cell differentiation toward Th17-mediated inflammation, with relevance to comorbid immune diseases such as Crohn’s disease and ulcerative colitis. IL-23 inhibition delivers high rates of complete/near-complete clearance with durable control enabled by extended dosing intervals and a favorable long-term safety record, including multi-year extension data without emergent serious infection or malignancy signals. Ongoing gaps include palmoplantar phenotypes, obesity-linked disease modulation, and treatment selection amid complex comorbidities.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

Highlighting Key IL-23 Innovations in Dermatology, With April W. Armstrong, MD, MPH

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

FDA News

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Orforglipron Availability, Amazon Pharmacy, and Dosing Considerations

Vaiibhav Patel, MD, is a cardiologist at the Ohio State University Wexner Medical Center.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The Current Diagnostic and Treatment Landscape of Cardiac Sarcoidosis, With Vaiibhav Patel, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Hosts are joined by Meena Bansal, MD, to discuss long-standing research gaps and what clinicians need to understand about sex-specific drivers of liver disease today.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Strategic Alliance Partnership

Liver Lineup: Closing the Gap in Women’s Liver Health

James Murrough, MD, PhD, from the Icahn School of Medicine at Mount Sinai.

Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Kv7 Channel Modulator Shows Promise for Anhedonia in MDD, With James Murrough, MD

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Can Gene Editing Be A 'Functional Cure' For Sickle Cell Disease?

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.


How the AAD Clinical Image Collection Can Help Dermatologists, With Vinod Nambudiri, MD, MBA, MPH

Experts discuss diagnostic challenges, variable presentations, and strategies to improve outcomes in Wilson disease.

From Diagnosis to Management: Addressing Gaps in Wilson Disease Care

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Results from the largest and longest trial of orforglipron to date have displayed the drug’s efficacy in reducing all-cause cardiovascular death and MACE incidence.

Breaking News

Type 2 Diabetes

ACHIEVE-4: Orforglipron Non-Inferior to Insulin Glargine for Cardiovascular Protection in T2D

Learn how subtle liver enzyme changes and age-specific movement symptoms signal Wilson disease, plus the latest on newborn screening and tests.

Video Series

Early Clinical Signs and the Evolution of Diagnosis in Wilson Disease

Psoriasis care shifts beyond skin: treat-to-target goals, heart risk reduction, and new oral TYK2 pills with strong safety data.

Latest News

AACE Annual Meeting 2026 Preview: 7 Trials to Know

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average

Understanding Patient Preferences in Psoriasis, With Andrew Blauvelt, MD, MBA

Highlighting Key IL-23 Innovations in Dermatology, With April W. Armstrong, MD, MPH